Kathleen Madden

614 total citations
21 papers, 287 citations indexed

About

Kathleen Madden is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kathleen Madden has authored 21 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kathleen Madden's work include Cancer Immunotherapy and Biomarkers (7 papers), Melanoma and MAPK Pathways (6 papers) and CAR-T cell therapy research (3 papers). Kathleen Madden is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Melanoma and MAPK Pathways (6 papers) and CAR-T cell therapy research (3 papers). Kathleen Madden collaborates with scholars based in United States. Kathleen Madden's co-authors include Anna C. Pavlick, Mary Kate Kasler, Devon Chabot‐Richards, Patrick A. Ott, John G. Golfinos, Erik Parker, Ashwatha Narayana, Moses Tam, Roy A. Raad and Brianna Hoffner and has published in prestigious journals such as Journal of Clinical Oncology, Critical Care Medicine and Transfusion.

In The Last Decade

Kathleen Madden

20 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathleen Madden United States 9 165 110 107 57 40 21 287
Camille L. Gérard Switzerland 10 196 1.2× 97 0.9× 85 0.8× 80 1.4× 27 0.7× 33 300
Prachi Bhave Australia 7 232 1.4× 71 0.6× 65 0.6× 54 0.9× 26 0.7× 22 298
Takayuki Takimoto Japan 10 101 0.6× 63 0.6× 139 1.3× 26 0.5× 20 0.5× 51 289
Lorenz Jost Switzerland 8 142 0.9× 79 0.7× 102 1.0× 99 1.7× 23 0.6× 11 342
Sara Delfanti Italy 10 116 0.7× 58 0.5× 95 0.9× 43 0.8× 13 0.3× 32 254
Burhan Abdullah Zaman Iraq 6 136 0.8× 80 0.7× 25 0.2× 77 1.4× 33 0.8× 14 277
Cor H. van der Leest Netherlands 7 206 1.2× 44 0.4× 110 1.0× 93 1.6× 11 0.3× 16 289
Jeryl Villadolid United States 4 311 1.9× 65 0.6× 77 0.7× 97 1.7× 33 0.8× 4 398
Lucie Heinzerling Germany 8 146 0.9× 70 0.6× 52 0.5× 51 0.9× 13 0.3× 22 210
Jason Cham United States 8 272 1.6× 61 0.6× 84 0.8× 173 3.0× 15 0.4× 20 355

Countries citing papers authored by Kathleen Madden

Since Specialization
Citations

This map shows the geographic impact of Kathleen Madden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Madden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Madden more than expected).

Fields of papers citing papers by Kathleen Madden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Madden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Madden. The network helps show where Kathleen Madden may publish in the future.

Co-authorship network of co-authors of Kathleen Madden

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Madden. A scholar is included among the top collaborators of Kathleen Madden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Madden. Kathleen Madden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berger, Assaf, Kenneth Bernstein, Joshua S. Silverman, et al.. (2022). Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. Journal of Neuro-Oncology. 158(3). 471–480. 7 indexed citations
2.
Raval, Jay S., Kathleen Madden, Matthew D. Neal, & Sarah A. Moore. (2021). Anti‐D alloimmunization in Rh(D) negative adults with severe traumatic injury. Transfusion. 61(S1). S144–S149. 13 indexed citations
3.
Madden, Kathleen & Jay S. Raval. (2019). Review of whole blood use in trauma. ISBT Science Series. 14(3). 282–288. 2 indexed citations
4.
Madden, Kathleen & Mary Kate Kasler. (2019). Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Seminars in Oncology Nursing. 35(5). 150932–150932. 34 indexed citations
5.
Madden, Kathleen, et al.. (2019). 1482: ESTABLISHING A WHOLE BLOOD RESUSCITATION PROGRAM FOR TRAUMATIC HEMORRHAGIC SHOCK: A NEEDS ASSESSMENT. Critical Care Medicine. 48(1). 717–717. 1 indexed citations
6.
Carreau, Nicole A., et al.. (2018). Immunotherapy efficacy and safety in elderly cutaneous malignancy patients.. Journal of Clinical Oncology. 36(15_suppl). e21524–e21524. 2 indexed citations
7.
Madden, Kathleen & Devon Chabot‐Richards. (2018). HLA testing in the molecular diagnostic laboratory. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 474(2). 139–147. 26 indexed citations
8.
Madden, Kathleen, et al.. (2018). BRAF/MEK Inhibition in Melanoma: An Update. Journal of the Advanced Practitioner in Oncology. 9(7). 2 indexed citations
9.
Raad, Roy A., et al.. (2017). Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma. Clinical Nuclear Medicine. 42(7). e345–e346. 18 indexed citations
10.
11.
Matheson, Paul J., et al.. (2015). Alterations in platelet-derived growth factor expression in the pathophysiology of necrotizing enterocolitis. Journal of Surgical Research. 198(2). 377–383.
12.
Pavlick, Anna C., Sunandana Chandra, Claire Stein, et al.. (2014). Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.. Journal of Clinical Oncology. 32(15_suppl). e20025–e20025. 4 indexed citations
13.
Madden, Kathleen, et al.. (2014). Primer on Immuno-Oncology and Immune Response. Clinical journal of oncology nursing. 18(3). 311–317. 7 indexed citations
14.
Narayana, Ashwatha, Moses Tam, Kathleen Madden, et al.. (2013). Vemurafenib and radiation therapy in melanoma brain metastases. Journal of Neuro-Oncology. 113(3). 411–416. 85 indexed citations
15.
Chandra, Sunandana, et al.. (2013). Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma.. Journal of Clinical Oncology. 31(15_suppl). 9063–9063. 7 indexed citations
16.
Rubin, Krista M., et al.. (2012). Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse’s perspective. Supportive Care in Cancer. 20(8). 1601–1611. 11 indexed citations
17.
Ott, Patrick A., Kathleen Madden, Xin Cheng, et al.. (2012). Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemotherapy and Pharmacology. 71(1). 183–191. 34 indexed citations
18.
Pavlick, Anne C., et al.. (2010). Hair depigmentation as an indicator of durable response to CTLA-4 therapy.. Journal of Clinical Oncology. 28(15_suppl). 8571–8571. 11 indexed citations
19.
Pavlick, Anne C., Patrick A. Ott, Juliet Escalon, et al.. (2009). Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. Journal of Clinical Oncology. 27(15_suppl). 9080–9080. 1 indexed citations
20.
Pavlick, Anne C., Juliet Escalon, Kathleen Madden, et al.. (2008). A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH. Journal of Clinical Oncology. 26(15_suppl). 9027–9027. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camille L. Gérard Breakdown of academic impact, for papers by Prachi Bhave Breakdown of academic impact, for papers by Takayuki Takimoto Breakdown of academic impact, for papers by Lorenz Jost Breakdown of academic impact, for papers by Sara Delfanti Breakdown of academic impact, for papers by Burhan Abdullah Zaman Breakdown of academic impact, for papers by Cor H. van der Leest Breakdown of academic impact, for papers by Jeryl Villadolid Breakdown of academic impact, for papers by Lucie Heinzerling Breakdown of academic impact, for papers by Jason Cham
Rankless by CCL
2026